Symmetry Partners LLC Sells 403 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Symmetry Partners LLC cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 23.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,346 shares of the biopharmaceutical company’s stock after selling 403 shares during the quarter. Symmetry Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $967,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. NewSquare Capital LLC lifted its stake in Regeneron Pharmaceuticals by 1,450.0% during the 1st quarter. NewSquare Capital LLC now owns 31 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 29 shares in the last quarter. Sunbelt Securities Inc. bought a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at about $25,000. Steward Financial Group LLC purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $28,000. Householder Group Estate & Retirement Specialist LLC grew its position in Regeneron Pharmaceuticals by 1,750.0% in the 1st quarter. Householder Group Estate & Retirement Specialist LLC now owns 37 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 35 shares in the last quarter. Finally, Manchester Capital Management LLC increased its stake in Regeneron Pharmaceuticals by 740.0% in the 1st quarter. Manchester Capital Management LLC now owns 42 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 37 shares during the last quarter. Institutional investors own 84.15% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Canaccord Genuity Group upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their target price for the stock from $720.00 to $992.00 in a research note on Monday, August 21st. 500.com restated a “maintains” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 28th. BMO Capital Markets lifted their target price on Regeneron Pharmaceuticals from $960.00 to $985.00 and gave the stock an “outperform” rating in a research note on Monday, August 21st. Barclays increased their price target on shares of Regeneron Pharmaceuticals from $900.00 to $925.00 and gave the company an “overweight” rating in a research report on Monday, August 21st. Finally, 22nd Century Group reaffirmed a “downgrade” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 28th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $903.27.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $832.38 on Friday. The firm has a 50 day moving average of $781.64 and a 200-day moving average of $774.14. The firm has a market capitalization of $90.36 billion, a P/E ratio of 22.00, a price-to-earnings-growth ratio of 2.46 and a beta of 0.19. Regeneron Pharmaceuticals, Inc. has a 12 month low of $668.00 and a 12 month high of $847.50. The company has a current ratio of 5.45, a quick ratio of 4.64 and a debt-to-equity ratio of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $10.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.48 by $1.76. The business had revenue of $3.16 billion for the quarter, compared to analysts’ expectations of $3.02 billion. Regeneron Pharmaceuticals had a net margin of 33.93% and a return on equity of 19.19%. The business’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same period in the prior year, the company posted $9.77 EPS. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.42 earnings per share for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 12,280 shares of the company’s stock in a transaction dated Wednesday, August 23rd. The stock was sold at an average price of $839.97, for a total value of $10,314,831.60. Following the transaction, the director now directly owns 2,037 shares in the company, valued at approximately $1,711,018.89. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $716.88, for a total value of $71,688.00. Following the completion of the transaction, the director now owns 18,747 shares of the company’s stock, valued at approximately $13,439,349.36. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Christine A. Poon sold 12,280 shares of the firm’s stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $839.97, for a total transaction of $10,314,831.60. Following the sale, the director now owns 2,037 shares in the company, valued at approximately $1,711,018.89. The disclosure for this sale can be found here. Over the last quarter, insiders sold 32,521 shares of company stock valued at $27,232,176. Company insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.